Impact of PSA nadir, PSA response and time to PSA nadir on overall survival in real‐world setting of metastatic hormone‐sensitive prostate cancer patients

Abstract

In times of combination therapies for mHSPC, a PSA nadir of respectively, <0.2 and <0.02 ng/mL are associated with best OS rates. Moreover, a relative PSA response ≥99% and a longer TTN are clinical important proxies for favorable OS estimates.